Cefdinir--A New Oral Cephalosporin
Cefdinir (Omnicef - Parke-Davis), a third-generation oral cephalosporin, has been approved by the FDA for treatment of acute sinusitis, otitis media, acute exacerbations of chronic bronchitis, pharyngitis, community-acquired pneumonia and skin infections. Other drugs available for these indications are reviewed in The Medical Letter Handbook of Antimicrobial Therapy, 1998....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Cefdinir--A New Oral Cephalosporin
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1034
Article Code: 1034a
Date: August 28, 1998
Volume: 40
Pages: 85-87
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1034
Article Code: 1034a
Date: August 28, 1998
Volume: 40
Pages: 85-87
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)